AI assistant
AB Science — Capital/Financing Update 2010
Apr 21, 2010
1059_iss_2010-04-21_006da423-1597-4dc5-875f-9c6f92a41a48.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
Paris,%April%21st%2010,%8%am
Initial!public!offering!of!AB!Science!on!NYSE!Euronext
Revised!terms!and!conditions
- Indicative!price!range!between!12.30€!and!13.00€ per!share
- Size!of! the!Offering:!726,820!existing!shares!and!1,305,700!newly!issued!shares,!or!25.7 M€! (on! the!basis!of!the!mid!point!of!the!initial!public!offering!price!range)
- An!extension!clause :!up!to!304,878!supplementary!existing!shares
- OverRallotment!option :!up!to!350,609 supplementary!existing!shares
- Subscription!period!is! expected! to! end!on!April! 22nd! 2010,! for!both! the!Public!Offering!and! the! Global!Placement
- Final!offering!price!expected!on!April!23rd!2010,!and!trading!on!Euronext!Paris!(Compartment!B)!is! expected!on!April!26th!2010
AB!Science!has! revised! the! terms!and!conditions!of!its!initial!public!offering!and!proposed!listing!of!its shares!on!Euronext!Paris,!Compartment!B.!
The%targeted%gross%proceeds%from%the%issue%of%new%shares%during%the%Public%Offering%in%France%and%Global% Placement%should%be%approximately%16.5%M€%(versus%20.2%M€%initially%planned%in%the%Prospectus%approved% by%the%AMF%on%April%07th%2010%under%the%number%10L084).
The%Public%offering%in%France%and%the%Global%placement%will%close%on%April%22nd%2010%at%17:00%(Paris%time).% The%settlement%and%delivery%is%planned%on%April%28th%2010,%and%trading%should%start%on%April%26th%2010.
New%terms%and%conditions%of%the%Offering%are%as%follows:
Number!of!shares!offered!in!the!Public!Offering!and!Global!Placement:
Offering! :! 2,032,520% shares% offered,% including% 1,305,700% new% shares% to% be% issued% and% 726,820% existing% shares%to%be%sold,%i.e.%an%overall%amount%of%25.7%M€.
Indicative!price!range:!12.30%€%L%13.00%€
Extension! clause:! The% number% of% shares% offered% may% be% increased% by% a% maximum% of% 304,878% supplementary%existing%shares%to%be%sold,%i.e.%15%%of%the%initial%offering.
OverRallotment! option:! The% number% of% shares% offered% may% be% increased% by% a% maximum% of% 350,609% supplementary%existing%shares%to%be%sold,%i.e.%15%%of%the%initial%offering%(including the%Extension%clause).
If!the!extension!clause!and!overRallotment!option!are!exercised,!gross%proceeds%from%the%Offering%should% amount%to%34.0%M€%(of%which%16.5%M€%from%newly%issued%shares%and%17.5%M€%for the%selling%shareholders).
The indicative timetable of the Offering, as extended on April 20th 2010, stands as follows:
| 21 April 2010 | Nyse Euronext notice relative to the revised terms and conditions of the Offering |
|---|---|
| Release of a financial notice in the newspaper la Tribune | |
| 22 April 2010 | Close of the OPO and the Global placement (17h Paris time) |
| 23 April 2010 | Fixing of the final Price of the Offering by the Board of Directors |
| Nyse Euronext notice relative to the result of the OPO | |
| Press release indicating the final price and number of shares of the Offering | |
| 26 April 2010 | Start of trading on Euronext Paris |
| 28 April 2010 | Settlement/delivery |
| 21 May 2010 | Deadline for exercising the Over-allotment option |
| End of stabilization period |
Revocability of orders issued in the OPO:
Orders issued in the OPO before release of the financial notice in La Tribune on April 21st 2010 shall be maintained except where they are expressly revoked before April 22nd 2010 (17:00 hours Paris time). New irrevocable orders may be issued up to and including April 22nd 2010.
The French securities regulator (l'Autorité des marchés financiers - the AMF) granted visa n° 10-084 on April 7th 2010 to the Prospectus relating to AB Science's initial public offering, comprising its Document de base registered on February 10th under number 1.10-006, an update of the Document de base filed with the AMF on April $7th$ and a Note d'opération (including the summary of the Prospectus).
Banking syndicate
Contact
Lead manager and bookrunner
Fortis Bank Nederland
Joint lead manager: Fortis Bank Nederland
Public information
The legal and financial documents required to be made available to shareholders may be consulted at the registered office of the Company, 3 avenue George V, 75008 Paris.
Copies of the Prospectus are available free of charge from the Company and from the Lead Manager and Bookrunner and the Joint-Lead Manager. The Prospectus may be viewed on the websites of the Company (www.ab-science.com) and the AMF (www.amf-france.org).
The attention of investors is drawn to Section 4, "Risk Factors", contained in the Document de base registered with the AMF, the update of such Document de base filed with the AMF and to Section 2 "Risk Factors" contained in the Note d'opération.
About AB Science
Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a new class of targeted molecules whose action is to modify signalling pathways within cells. Through these PKIs, the Company targets diseases with high unmet medical needs (cancer, inflammatory diseases and central nervous system diseases), in both human and veterinary medicines. Thanks to its extensive research and development capabilities, AB Science has its own portfolio of molecules. masitinib, a lead compound, has already been reaistered in veterinary medicine in Europe and is pursuing three on-going phases 3 in human medicine in pancreatic cancer, GIST and mastocytosis.
More information on AB Science's website: www.ab-science.com
Citigate Dewe Rogerson
Agnès Villeret - Tel: +33 1 53 32 78 95 - [email protected] Matthieu Pirouelle - Tel : +33 1 53 32 84 77 - [email protected]
Disclaimer
This\$press\$release,\$together\$with\$the\$material\$set\$ forth\$herein,\$does\$not\$constitute\$an\$offer\$of\$securities\$ for\$sale\$nor\$the\$solicitation\$of\$an\$offer\$to\$purchase\$securities\$in\$any\$jurisdiction.\$Distribution\$of\$such\$press\$ release\$in\$certain\$jurisdiction\$may\$constitute\$a\$breach\$of\$applicable\$laws\$and\$regulation.
In\$particular:
This\$press\$ release\$does\$not\$constitute\$an\$offer\$ to\$sell\$or\$ the\$solicitation\$of\$an\$offer\$ to\$buy\$any\$ financial\$ instruments\$in\$ the\$United\$States.\$Securities\$mentioned\$in\$ this\$ document\$ have\$ not\$ been\$ and\$will\$ not\$ be\$ registered\$under\$the\$Securities\$Act\$of\$1933,\$as\$amended\$(the\$"Securities\$Act")\$and\$may\$not\$be\$offered\$or\$ sold\$in\$ the\$United\$States\$absent\$registration\$or\$an\$exemption\$ from\$ the\$registration\$requirements\$of\$ the\$ Securities\$Act.\$Any\$public\$offer\$of\$securities\$in\$the\$United\$States\$shall\$be\$made\$by\$means\$of\$a\$prospectus\$ that\$ may\$ be\$ obtained\$ from\$ the\$ issuer\$ containing\$ detailed\$ information\$ regarding\$ the\$ Company,\$ its\$ management\$and\$financial\$statements.\$The\$Company\$does\$not\$intend\$to\$register\$this\$offering\$in\$all\$or\$in\$ part\$or\$to\$make\$a\$public\$offer\$of\$securities\$in\$the\$United\$States.
This\$ press\$ release\$ is\$ not\$ an\$ invitation\$ nor\$ is\$ it\$ intended\$ to\$ be\$ an\$ inducement\$ to\$ engage\$ in\$ investment\$ activity\$ for\$ the\$ purpose\$ of\$ section\$ 21\$ of\$ the\$ Financial\$ Services\$ and\$ Markets\$ Act\$ 2000,\$ as\$ amended ("FSMA").\$ This\$ document\$ is\$ directed\$ only\$ at\$ (i)\$ persons\$ outside\$ the\$ United\$ Kingdom;\$ or\$ (ii)\$ persons\$ in\$ the\$ United\$ Kingdom\$ that\$ are\$ "qualified\$ investors"\$ within\$ the\$ meaning\$ of\$ Article\$ 2(1)(e)\$ of\$ Directive\$2003/71/EC\$including\$any\$relevant\$implementing\$measure\$in\$each\$member\$state,\$that\$are\$also\$ (a)\$ persons\$ authorised\$ under\$ FSMA\$ or\$ otherwise\$ having\$ professional\$ experience\$ in\$ matters\$ relating\$ to\$ investments\$ and\$ qualifying\$ as\$ investment\$ professionals\$ under\$ article\$ 19\$ of\$ the\$ Financial\$ Services\$ and\$ Markets\$Act\$2000\$ (Financial\$Promotion)\$Order\$2005,\$as\$amended\$ (the\$"Financial\$Promotion\$Order");\$or\$ (b)\$institutions\$ or\$corporations\$ qualifying\$ as\$ high\$ net\$worth\$ persons\$ under\$Article\$ 49(2)(a)\$ to\$ (d)\$ of\$ the\$ Financial\$Promotion\$Order;\$or\$(c)\$any\$other\$persons\$to\$whom\$this\$document\$for\$the\$purposes\$of\$Section\$ 21\$ of\$ FSMA\$ can\$ otherwise\$ lawfully\$ be\$ made\$ (all\$ such\$ persons\$ together\$ being\$ referred\$ to\$ as\$ "Relevant\$ Persons").\$Any\$person\$in\$the\$United\$Kingdom\$that\$is\$not\$a\$Relevant\$\$Person\$should\$not\$act\$or\$rely\$on\$this\$ document.
This\$document\$contains\$forwardRlooking\$statements.\$No\$guarantee\$can\$be\$given\$as\$to\$any\$of\$the\$events\$ anticipated\$ by\$ the\$ forwardRlooking\$ statements,\$ which\$ are\$ subject\$ to\$ inherent\$ risks,\$ including\$ those\$ described\$ in\$ the\$ Prospectus,\$ changes\$ in\$ economic\$ conditions,\$ the\$ financial\$ markets\$ or\$ the\$ markets\$ in\$ which\$AB\$Science\$operates.
Société\$ Générale,\$ acting\$ as\$ stabilizing\$ agent,\$ or\$ any\$ institution\$ acting\$ on\$ its\$ behalf\$ (the\$ "Stabilizing\$ Agent")\$may,\$during\$a\$period\$of\$30\$days\$following\$the\$date\$on\$which\$the\$offering\$price\$is\$determined,\$ie,\$ according\$to\$the\$indicative\$timetable,\$ from\$April\$23\$to\$May\$21,\$2010,\$effect\$transactions\$with\$a\$view\$to\$ maintaining\$ the\$ market\$ price\$ of\$ AB\$ Science\$ shares\$ in\$ a\$ manner\$ consistent\$ with\$ applicable\$ laws\$ and\$ regulations\$ and,\$ in\$ particular,\$ EU\$ Commission\$ regulation\$ no\$ 2273/03\$ of\$December\$ 22,\$ 2003.\$However,\$ there\$ is\$ no\$ assurance\$ that\$ the\$ Stabilizing\$ Agent\$ will\$ take\$ any\$ stabilizing\$ action\$ and,\$ if\$ begun,\$ such\$ stabilizing\$action\$may\$be\$interrupted\$at\$any\$time.\$Any\$stabilizing\$action\$may\$affect\$the\$price\$of\$AB\$Science\$ shares\$and\$could\$result\$in\$market\$prices\$for\$the\$shares\$higher\$than\$those\$which\$might\$otherwise\$prevail.